CorMedix Inc. (NASDAQ:CRMD) Q1 2023 Earnings Call May 15, 2023 4:30 PM ET

Company Participants

Joe Todisco - Chief Executive Officer

Matt David - Executive Vice President and Chief Financial Officer

Phoebe Mounts - Executive Vice President and General Counsel

Erin Mistry - Executive Vice President and Chief Commercial Officer

Conference Call Participants

Serge Belanger - Needham & Company

Operator

Good afternoon, and welcome to the CorMedix First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]. Please note, this event is being recorded.

I would now like to turn the conference over to [Vanita Kossi] (ph). Please go ahead.

Unidentified Company Representative

Thank you. Good afternoon, everyone, and welcome to the CorMedix first quarter 2023 earnings conference call. Leading the call today is Joe Todisco, Chief Executive Officer of CorMedix; and he is joined by Dr. Matt David, Executive Vice President and CFO; Dr. Phoebe Mounts, EVP and General Counsel and Erin Mistry, EVP and Chief Commercial Officer.

Before we begin, I would like to remind everyone that during the call management may make what are known as forward-looking statements within the meaning set forth in the Private Securities Litigation Reform Act of 1995. These statements are subject to certain risks and uncertainties and include but are not limited to any of the following.

Any statements other than statements of historical fact regarding management's expectations, beliefs, goals, and plans about company's prospects, including its clinical development program, manufacturing activities and NDA approval for DefenCath in the U.S. or other product candidates, future financial position, future revenues and projected costs and potential market acceptance of DefenCath or other product candidates.

More specifically, forward-looking statements include any statements about our clinical development plans, the timing, cost, progress, results, estimates and interpretations thereof, projections as to the company's future capital raising and spending and cash position, expectations to the timing and nature of anticipated regulatory actions, possible product licensing, business development or other transactions, any commercial plans and expectations, market projections for our product candidates, and expectations as to manufacturing and product component costs.

Actual results may differ materially from these projections or estimates due to a variety of important factors, including but not limited to uncertainties related to clinical development, regulatory approvals, and commercialization. These risks are described in greater detail in CorMedix's filing with the SEC, including the latest quarterly report on Form 10-Q and annual report on Form 10-K, copies of which are available free of charge at the SEC's website at www.sec.gov or upon request from CorMedix.